BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15380269)

  • 1. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro.
    Heller I; Leitner S; Dierich MP; Lass-Flörl C
    Int J Antimicrob Agents; 2004 Oct; 24(4):401-4. PubMed ID: 15380269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
    Singh J; Rimek D; Kappe R
    Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism of CAY-1 with amphotericin B and itraconazole.
    De Lucca AJ; Bland JM; Boue S; Vigo CB; Cleveland TE; Walsh TJ
    Chemotherapy; 2006; 52(6):285-7. PubMed ID: 17008779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.
    Meletiadis J; te Dorsthorst DT; Verweij PE
    Int J Antimicrob Agents; 2006 Nov; 28(5):439-49. PubMed ID: 17055706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
    Mosquera J; Sharp A; Moore CB; Warn PA; Denning DW
    J Antimicrob Chemother; 2002 Aug; 50(2):189-94. PubMed ID: 12161398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
    Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
    J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B.
    Moore CB; Walls CM; Denning DW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1882-5. PubMed ID: 11353643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans.
    Mahboubi M; Ghazian Bidgoli F
    Phytomedicine; 2010 Aug; 17(10):771-4. PubMed ID: 20189786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
    Te Dorsthorst DT; Verweij PE; Meis JF; Punt NC; Mouton JW
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2007-13. PubMed ID: 15155192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.